The QualityStocks Daily Monday, June 28th, 2021

Today's Top 3 Investment Newsletters

MarketClub Analysis(MRIN) $7.5000 +96.85%

QualityStocks(ACBM) $2.3900 +54.19%

Schaeffer's(NTLA) $133.4300 +50.21%

The QualityStocks Daily Stock List

Bellus Health (BLU)

MarketClub Analysis, MarketBeat, Streetwise Reports, TradersPro, TradersPro Morning, StreetAuthority Financial, Schaeffer's and InvestorPlace reported earlier on Bellus Health (BLU), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Bellus Health Inc. (NASDAQ: BLU) (TSE: BLU) (FRA: BHNO) is a clinical-stage biopharmaceutical firm that is engaged in the research and development of new therapies to treat chronic pruritus, chronic itch and chronic cough, among other hypersensitization disorders.

The firm has its headquarters in Laval, Canada and was incorporated in 1993, on June 17th. It operates as part of the heathcare sector, under the biotech and pharma sub-industry.

The company holds economic interests in partnered clinical-stage drug development programs, which include ALZ-801 for APOE4 homozygous Alzheimer’s disease, AMO-01 for Fragile X Syndrome and KIACTA for sarcoidosis. It operates through the development of drug candidates for the health solutions segment.

The enterprise’s pipeline includes a potent, orally bio-available selective small molecule P2X3 receptor antagonist dubbed BLU-5937, which is indicated for the treatment of chronic cough. It is currently undergoing a phase 2 clinical trial. The candidate also has the potential to treat patients suffering from the aforementioned ailments who do not respond to standard treatments. In addition to this, the enterprise is also developing treatments for the chronic itch and chronic pruritus. It is currently studying how P2X3 activation contributes to pain and irritation and if P2X3 receptor inhibition can assist in treating other afferent disorders that are linked to hypersensitization.

The firm’s BLU-5937 candidate is positioned as a potential competitive treatment option in a market with significant unmet medical needs and potentially huge market opportunities. The candidate’s success will not only address patients’ unmet medical needs but will also extend the company’s consumer reach, which will in turn, boost the firm’s growth.

Bellus Health (BLU), closed Monday’s trading session at $3.28, off by 0.906344%, on 225,503 volume. The average volume for the last 3 months is 513,966 and the stock's 52-week low/high is $2.00999999/$12.0299997.

Adial Pharmaceuticals (ADIL)

MarketClub Analysis, StockMarketWatch, BUYINS.NET, TopPennyStockMovers, QualityStocks, StreetInsider, Small Cap Firm, Schaeffer's, PoliticsAndMyPortfolio and MarketBeat reported earlier on Adial Pharmaceuticals (ADIL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Adial Pharmaceuticals Inc. (NASDAQ: ADIL) is a clinical-stage biopharmaceutical firm that is engaged in developing treatments for preventing or treating addiction and associated disorders.

The firm has its headquarters in Charlottesville, Virginia and was incorporated in November 2010 by Bankole A. Johnson. It operates as part of the pharmaceutical manufacturing industry, under the healthcare sector, in the biotech and pharma sub-industry and serves consumers in Virginia.

The enterprise’s pipeline is made of a selective serotonin-3 antagonist dubbed AD04, which is indicated for treating alcohol use disorder. The active ingredient in the formulation, i.e. ondansetron, is the serotonin-3 antagonist. The formulation has also been indicated for the treatment of other addictive disorders including smoking, obesity and opioid use disorder, among other drug addictions. The candidate recently concluded its phase 2b study which tested its effectiveness in treating alcohol use disorders, and it demonstrated promising results in decreasing the quantity and frequency of heavy drinking and drinking in general, with no noticeable safety concerns. The enterprise also develops AD01, which is indicated for treating addictive behaviors, and recently concluded phase 1 trials. In addition to this, the enterprise is also involved in the development of drug candidates for non-opioid pain alleviation and other disorders and ailments.

The firm is planning to venture into the genetic testing market after receiving a patent for its AD04 candidate, bringing the firm one step closer to helping identify patients that could benefit from their formulation. This move will also allow the firm to commercialize a companion diagnostic test to AD04 in the future, which will help extend its consumer reach and in turn, bring in even more investors.

Adial Pharmaceuticals (ADIL), closed Monday’s trading session at $2.73, up 10.0806%, on 8,552,396 volume. The average volume for the last 3 months is 827,290 and the stock's 52-week low/high is $1.13999998/$4.00.

Aethlon Medical (AEMD)

Tip.us, Investor Ideas, QualityStocks, StockMarketWatch, Red Chip, Streetwise Reports, PennyStocks24, BUYINS.NET, OTCPicks, MarketBeat, FeedBlitz, TraderPower, StreetInsider, MarketClub Analysis, MicroCap Gems, AllPennyStocks, SmallCapVoice, RedChip, PennyStockRumors.net, Pennybuster, Clutch Investments, OTC Picks, PricelessPennyStocks, TradersPro, StockBlogs, Trading Concepts, BestStockChoice, TopPennyStockMovers, DrStockPick, Faisam Trader, The Online Investor, INO Market Report, PennyOmega, Investing Futures, WallStreet Advisors, InvestorPlace, InvestorsUnderground, Stock Castle, SmallCapStockPlays, SmallCap Network, Nebula Stocks, PennyTrader Publisher, Actual Gains and Investing Daily reported earlier on Aethlon Medical (AEMD), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Aethlon Medical Inc. (NASDAQ: AEMD) (FRA: EJU) is a medical technology firm that is engaged in the development of products that help in diagnosing and treating organ and life threatening ailments in the U.S.

The firm has its headquarters in San Diego, California and was incorporated in May 1998 by James A. Joyce. It is a part of the scientific and technical instruments manufacturing industry and operates in the health care industry, under the medical equipment and devices sub-industry.

The company is party to a collaboration agreement with the University of Pittsburgh which entails research on neck and head cancers. It operates through the ESI and Aethlon segments. The latter segment is involved in diagnostic business activities while the former segment deals with therapeutic business activities.

The enterprise offers a platform that develops medical equipment to target the selective removal of ailment-promoting particles from an individual’s circulatory system, known as ADAPT. Its product pipeline is made of an exosomal biomarker candidate known as TauSome, which diagnoses chronic traumatic encephalopathy in people. In addition to this, the enterprise also develops a clinical-stage immunotherapeutic device known as the Aethlon Hemopurifier, which removes life-threatening viruses and exosomes from the body’s circulatory system. These exosomes aid in the progression of infectious viral pathogens like Hepatitis C and HIV as well as cancer.

The firm recently published case studies of 2 coronavirus patients who were treated with its Hemopurifier, with its CEO noting that their device may play a crucial role in filtering out exosomes, adding that their device was able to clear the SARS-CoV-2 virus from both patients’ bloodstream. The device’s success in treating both patients may bring in more investors into the firm and push share prices higher.

Aethlon Medical (AEMD), closed Monday’s trading session at $5.17, up 0.976562%, on 957,819 volume. The average volume for the last 3 months is 5.412M and the stock's 52-week low/high is $1.21899998/$12.4899997.

Arbutus Biopharma (ABUS)

MarketBeat, BUYINS.NET, MarketClub Analysis, StockMarketWatch, Marketbeat.com, TraderPower, Daily Trade Alert, Schaeffer's, Zacks, Trades Of The Day, TradersPro, StreetInsider, Profitable Trader Authority, InvestorsUnderground, Money Morning, OTCtipReporter, Barchart, PennyStockScholar, QualityStocks, Streetwise Reports, The Street and PennyStockProphet reported earlier on Arbutus Biopharma (ABUS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Arbutus Biopharma Corporation (NASDAQ: ABUS) (FRA: 19DN) is a biopharmaceutical firm that is focused on discovering, developing and commercializing cures for patients who suffer from the HBV infection in the U.S. (chronic Hepatitis B virus).

The firm has its headquarters in Warminster, Pennsylvania and was incorporated in 2007. Prior to its name change in July 2015, the firm was known as Tekmira Pharmaceuticals Corporation. It operates in the healthcare sector, under the biotech and pharma sub-industry and serves consumers in Canada and the U.S. The firm’s subsidiaries include Arbutus Biopharma US Holdings Inc. and Arbutus Inc.

The company’s objective is to develop a curative combination regiment for the chronic Hepatitis B virus infection and formulate a suite of products that intervene at various points in the virus’ life cycle and reactivate the host’s immune system. The company is also involved in the licensing of lipid nanoparticle technology. It is party to research collaboration, licensing and alliance agreements with Acuitas Therapeutics Inc., Alnylam Pharmaceuticals Inc., Gritstone Oncology Inc. and Marqibo.

The enterprise’s product pipeline includes an oral capsid inhibitor dubbed AB-836 indicated for HBV DNA replication suppression and a subcutaneously-delivered RNA candidate dubbed AB-729, which decreases HBV antigens through the use of GalNAc delivery technology and is currently undergoing a phase 1 clinical trial. The enterprise also has research and development programs, including an oral PD-L1 inhibitor that reawakens patients HBV immune response and HBV RNA destabilizers.

The firm has over the last year managed to increase its revenue by roughly 10% and with the Hepatitis B treatment market set to grow, the firm may soon bring in even heftier returns, which will in turn bring in more investments.

Arbutus Biopharma (ABUS), closed Monday’s trading session at $3.37, even for the day, on 7,575,557 volume. The average volume for the last 3 months is 1.461M and the stock's 52-week low/high is $1.71000003/$9.02000045.

Avenue Therapeutics (ATXI)

MarketBeat, Zacks, StreetInsider, StocksEarning, StockMarketWatch, TradersPro, Schaeffer's, Marketbeat.com, TradersPro Morning, SmallCapVoice, PoliticsAndMyPortfolio and MarketClub Analysis reported earlier on Avenue Therapeutics (ATXI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Avenue Therapeutics Inc. (NASDAQ: ATXI) (FRA: 49Y) is a specialty pharmaceutical firm that is engaged in the acquisition, licensing, development and commercialization of products that are mainly used in the intensive/acute care hospital setting.

The firm has its headquarters in New York and was incorporated in 2015, on February 9th. It operates in the healthcare sector, under the biotech and pharma sub-industry. The company is a majority-controlled subsidiary firm of Fortress Biotech Inc., which is a biopharmaceutical firm that is also engaged in the acquisition, development and commercialization of new biotechnology and pharmaceutical products.

The company develops intravenous Tramadol, which is currently undergoing phase 3 clinical trials for the treatment of moderate to severe post-surgical pain. The synthetic dual-acting opioid works by inhibiting noradrenaline and serotonin re-uptake and blocking spinal level nociceptive impulses and could be used as an alternative for conventional opioids. The oral formulation of this candidate is marketed in the U.S. for moderate to severe pain in grown-ups. Its parenteral formulations include subcutaneous and intramuscular formulations. The drug itself is marketed in the U.S. under the Ultram trade name. Ultracet, which is a combination product of acetaminophen and tramadol, is also sold in the U.S.

The firm is pursuing regulatory approval for its IV tramadol drug formulation, after the FDA cited in their Complete Response Letter that they did not find any controls, manufacturing or chemistry issues with its candidate. If successful, the firm will introduce the drug to the market, which will increase its revenue and boost share prices as well encourage more investments into the firm.

Avenue Therapeutics (ATXI), closed Monday’s trading session at $2.61, up 1.5564%, on 161,665 volume. The average volume for the last 3 months is 449,350 and the stock's 52-week low/high is $2.22000002/$12.3397998.

SolarWindow Technologies, Inc. (WNDW)

Tip.us, QualityStocks, StockOodles, InvestorPlace, NetworkNewsWire, SmallCapVoice, TopPennyStockMovers, TradersPro, PoliticsAndMyPortfolio, Market Intelligence Center Alert, Stock Gumshoe, StocksToBuyNow, Winston Small Cap, The Online Investor, AllPennyStocks and Wealth Insider Alert reported earlier on SolarWindow Technologies, Inc. (WNDW), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

SolarWindow Technologies, Inc. is a developer of next generation, transparent, electricity-generating SolarWindow™ coatings. The Company is a developer of electricity-generating windows for tall towers and skyscrapers. SolarWindow™ utilizes organic materials dissolved into liquid, best for low-cost high-output manufacturing. SolarWindow Technologies is headquartered in Columbia, Maryland.

SolarWindow™ systems can undergo installation on the readily-available sizeable window glass surfaces on tall towers and skyscrapers. SolarWindow™ can be applied to the sides of tall towers, generating electricity using natural, shaded, and artificial light. The coatings produce electricity on see-through glass and flexible plastics with colored tints popular to skyscraper glass. Upon application to glass or plastics, the coatings convert passive windows and other materials into electricity generators under natural, artificial, low, shaded, and reflected light conditions.

SolarWindow™ technology has been independently validated to generate 50-times the power of a conventional rooftop solar system. Moreover, it realizes a one-year payback when modeled on a 50-story building. SolarWindow Technologies’ latest products will be engineered as transparent, tinted, flexible veneers, which installers can apply directly over top of existing windows on tall towers and skyscrapers. This expanded product line extends the Company’s market reach beyond new and replacement installations, to include windows now installed on the estimated five million commercial buildings built in the U.S. alone. 

SolarWindow Technologies is expanding product development to include applying its electricity-generating coatings onto flexible glass – as thin as a business card (only 0.1-millimeter-thick), which is flexible enough to be bent without breaking or cracking.

In November, SolarWindow Technologies announced the completion of a $25 million equity financing. Kalen Capital Corporation (KCC), the family office of Mr. Harmel S. Rayat, Founder and Chairman of the company, invested roughly $24.9 million in this round.

Mr. John Conklin, President and Chief Executive Officer of SolarWindow Technologies, said, “This capital infusion marks a historical inflection point for SolarWindow and our nearly 15,000 shareholders. With this capital in hand and a decade of research and development behind us, we can now purchase equipment and hire personnel required for manufacturing of electricity-generating glass, a brand-new form of electrification.”

SolarWindow Technologies, Inc. (WNDW), closed Monday’s trading session at $7.9, up 20.6107%, on 252,854 volume. The average volume for the last 3 months is 161,015 and the stock's 52-week low/high is $2.33999991/$39.2000007.

Sun Pacific Holding (SNPW)

QualityStocks, OTCBB Journal, Broad Street, Today's Stock Tip, StocksImpossible, StockRockandRoll, StockHideout, Small Cap Firm, PennyStockLocks, Penny Stock 101, OTC Stock Review, MegaPennyStocks and Awesome Stock Tips reported earlier on Sun Pacific Holding (SNPW), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Sun Pacific Holding Corp. (OTC: SNPW) is a green energy firm that is focused on the provision of solar panel and lighting products in the U.S. It is engaged in the designing, development, building and management of green technologies.

The company was founded in 2009 and has its headquarters in Manalapan, New Jersey. Prior to its name change, the company was known as EXOlifestyle Inc. and operates as part of the electrical, plumbing and hardware wholesalers’ industry.

The firm is focused on using its experiences and capabilities in green energy solutions to help transform neighborhoods across the nation into smart cities. Its subsidiaries include Sun Pacific Security Corp., National Mechanical Corp., Bella Electrical LLC, Street Smart Outdoor Corp. and Sun Pacific Power Corp.

It provides advertising space on solar trash bins, solar digital shelters, bus benches and bus shelters, through one of its subsidiaries. Additionally, the firm offers plumbing, electrical and general contracting services to commercial and public customers. It is also engaged in the construction and development of a waste to energy plant in the state of Rhode Island. The firm’s energy lighting solutions and solar power bus shelters provide customers with turnkey systems.

The enterprise has a solid foundation which will aid in the growth of the company in a responsible and focused manner. In addition to this, the company is working on building valuable relationships and is set to expand into international markets through various partnerships and collaborations, with one of them entailing the development of a high efficiency off grid digital plug and play modular unit.

Sun Pacific Holding (SNPW), closed Monday’s trading session at $0.0406, up 22.8442%, on 11,270,447 volume. The average volume for the last 3 months is 8.849M and the stock's 52-week low/high is $0.00065/$0.349000006.

1847 Holdings LLC (EFSH)

RedChip, QualityStocks and Weekly Newsletter reported earlier on 1847 Holdings LLC (EFSH), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

1847 Holdings LLC is a unique publicly traded holding company platform. It combines the attractive attributes of private, lower-middle market businesses with the liquidity and transparency of a publicly traded company. The Company works to generate returns for shareholders in the future through consistent, annual distributions of operating subsidiary income and capital appreciation resulting from the timely sale of operating subsidiaries.

1847 Partners LLC serves as the manager of the company. 1847 Holdings LLC is headquartered in New York, New York. The Company lists on the OTC Markets.

1847 Holdings looks for businesses headquartered in North America and with Revenues of at least $5 million. Moreover, the Company looks for an historical Revenue growth rate of at least 5 percent. In addition, 1847 looks for companies that have current year EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of at least $1.5 million.

1847 Holdings’ intention is to provide shareholders with non-correlated returns. This is while permitting shareholders to liquidate their position in 1847 Holdings LLC at any point during an investment timeline. The Company's innovative structure allows flow-through tax treatment for shareholders.

1847 looks to derive value creation through prudently distributing annual income while growing its operating subsidiaries. This is in comparison to financial engineering fostered by extreme leverage. Therefore, 1847 Holdings seeks to own companies with founder-operators and management teams at the crucial inflection point in their growth cycle.

1847 Holdings previously announced it completed its acquisition of Asien’s Appliance. Asien’s is a California-based appliance retailer, which generated roughly $8.9 million (unaudited) and $13.3 million (unaudited) of Revenues in 2018 and 2019, respectively. In July, 1847 Holdings announced that its Asien’s Appliance subsidiary generated about $1.1 million in Total Sales in June 2020. This is up 21 percent over June 2019 Total Sales.

1847 Holdings LLC’s subsidiary, 1847 Goedeker, Inc. (NYSE American: GOED), also previously announced the closing of its initial public offering (IPO) of 1,111,200 shares of its common stock at a public offering price of $9.00 per share, for gross proceeds of $10,000,800, before deducting underwriting discounts and offering expenses. Furthermore, 1847 Goedeker granted the underwriters a 45-day option to purchase up to an additional 166,577 shares of common stock to cover over-allotments at the initial public offering price, less the underwriting discount.

The Company’s intention is to use the proceeds to pay off outstanding debt and obligations, and for working capital and general corporate purposes. 1847 Goedeker is a one-stop e-commerce destination for appliances, furniture, home goods, as well as related products.

1847 Holdings LLC (EFSH), closed Monday’s trading session at $2.25, up 20.9677%, on 11,850 volume. The average volume for the last 3 months is 879 and the stock's 52-week low/high is $0.819700002/$6.90000009.

Acro Biomedical Co., Ltd. (ACBM)

QualityStocks reported earlier on Acro Biomedical Co., Ltd. (ACBM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Acro Biomedical Co., Ltd. focuses on developing and marketing products that promote wellness and a healthy lifestyle. Its intention is to conduct research and development (R&D) on its own proprietary products based on cordyceps sinensis. The Company previously went by the name Killer Waves Hawaii, Inc. It changed its name to Acro Biomedical Co., Ltd. in January of 2017. Acro Biomedical is based in Fishers, Indiana.

Cordyceps sinensis has been described as a medicine in old Chinese medical books and Tibetan medicine. Cordyceps sinensis is a rare combination of a caterpillar and a fungus. It is found at altitudes above 4500m in Sikkim. Acro Biomedical originated from a group of scholars at the University of Taiwan. The Founder, Mr. Richard Chu, was looking for the materials for disease treatment and health care from traditional Chinese medicine and natural herbal medicine. The preferred material is China treasure, "Cordyceps".

The Company will operate in two main areas. These are health food development and new drug development. The first decade of Acro Biomedical was the development of scientific research to establish a combination of basic science. Since the founding of the Company, the target has always been scientific applications and market development.

The objective of establishing a technology and market integration business model centers on diverse areas. These include China, Southeast Asia, Northeast Asian, Central Asian and the Europe and United States market. Moreover, there are two special markets, one for the Chinese health industry market and one for the longevity of health care market.

Acro Biomedical Co., Ltd. (ACBM), closed Monday’s trading session at $2.39, up 54.1936%, on 1,650 volume. The average volume for the last 3 months is 2,150 and the stock's 52-week low/high is $1.00999999/$12.00.

Freddie Mac (FMCKL)

Real Pennies, QualityStocks and MarketClub Analysis reported earlier on Freddie Mac (FMCKL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Freddie Mac operates in the secondary mortgage market in the U.S. It buys residential mortgage loans originated by lenders, and also invests in mortgage loans and mortgage-related securities. Freddie Mac supports the housing market and the nation’s renters, homebuyers and homeowners throughout the entire nation and in all economic cycles. The Company is headquartered in McLean, Virginia and was chartered by Congress in 1970.

Freddie Mac operates by way of three business lines. These comprise Single-Family, Multifamily, and Capital Markets. The Company’s Single-Family business supports responsible, sustainable homeownership. Freddie Mac works with lenders of all sizes - national, regional, and community lenders and credit unions - to purchase conventional, conforming mortgage loans for one- to four-unit homes (including condominiums and manufactured homes) up to a certain dollar amount set by the Company’s regulator.

Freddie Mac Multifamily (working with a network of specialized vendors) provides funding for loans on properties ranging from five units to hundreds of units across manifold buildings. Moreover, the Company’s Capital Markets business promotes the mortgage market’s liquidity. It makes funding more available to borrowers through buying mortgage-related securities guaranteed by Freddie Mac and other financial institutions as investments and managing its portfolio.

Because it operates in the U.S. secondary mortgage market, Freddie Mac doesn’t lend directly to borrowers. The Company purchases loans that meet its standards from approved lenders. With the money that lenders receive in return, they can make loans to other qualified borrowers. In securitizing pools of mortgages and selling the securities to investors, Freddie Mac shifts a major portion of the credit risk associated with the loans it owns to private investors – away from taxpayers.

The Wall Street Journal reported this week that Freddie Mac is providing financing for a portfolio of over 300 rental homes under a now-defunct pilot program intended to help address the shortage of homes for middle-class families. The close to $26 million pact with Atlanta-based Promise Homes provides financing for these 300 affordable rental homes.

Freddie Mac (FMCKL), closed Monday’s trading session at $1.97, up 27.0968%, on 281,951 volume. The average volume for the last 3 months is 15,467 and the stock's 52-week low/high is $1.25/$10.25.

Noble Roman’s, Inc. (NROM)

QualityStocks, TaglichBrothers, MarketBeat, Wall Street Resources, The Bowser Report, Marketbeat.com, FeedBlitz, TopPennyStockMovers, StockOodles and SmallCapVoice reported earlier on Noble Roman’s, Inc. (NROM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Noble Roman's, Inc. sells and services franchises and licenses for non-traditional foodservice operations and stand-alone take-n-bake locations. The Company’s business model consists of three growth venues. These are Grocery Take-n-Bake Licensing; Non-Traditional Franchising; and Stand-Alone Franchising. The Company franchises and licenses under the Noble Roman’s Pizza, Noble Roman’s Take-N-Bake, Tuscano’s Italian Style Subs, and Noble Roman's Craft Pizza & Pub (CPP) trade names. Noble Roman’s is headquartered Indianapolis, Indiana.

The Company has awarded franchise and/or license agreements in all 50 U.S. States plus Washington, D.C. In addition, Noble Roman’s has awarded franchise and/or license agreements in Canada, Puerto Rico, the Bahamas, Italy, and the Dominican Republic.

Concerning the Company’s three growth venues,  Grocery Take-n-Bake Licensing involves licensing to sell Noble Roman’s Pizza. This is a component program using Noble Roman’s ingredients, in which delis assemble pizzas from standard Noble Roman’s ingredients.

Pertaining to Stand-Alone Venues, these are traditional pizzeria locations and Take-n-Bake locations. There is a merging over time between the kinds of Stand-Alone Venues: Live Yeast Dough; Hand-Rolled Breadsticks; and Baking Services.

Regarding Non-Traditional Venues, these are typically located in a host facility whose chief business is other than foodservice. These facilities can add pizza-focused foodservice as a Revenue Center; as a Facility Draw; and as an Employee Benefit.

On January 31, 2017, the first Noble Roman's Craft Pizza & Pub (CPP) opened in Westfield, Indiana. In May of 2018, the Company announced that it opened a fourth location of its new-generation, stand-alone pizzeria concept, Noble Roman's Craft Pizza & Pub (CPP) in Carmel, Indiana.

Noble Roman’s intention is to expedite the development of Craft Pizza & Pub (CPP) locations via franchising. General franchising is planned for Indiana and surrounding areas with an emphasis on franchisees that can become multi-unit operators. Moreover, the Company will also pursue development of other markets deemed suitable for the concept with experienced multi-unit operators.

Noble Roman's previously announced that it completed the roll-out of its new curbside carry-out service in all restaurant locations. The design of the Company's new curbside service for carry-out customers is to create added value and convenience. The program is called "Pizza Valet Service." With Pizza Valet Service, customers place orders ahead, drive into the restaurant's reserved valet parking spaces, and have their pizza run to their vehicle by specially uniformed pizza valets.

Noble Roman’s, Inc. (NROM), closed Monday’s trading session at $0.8, up 19.7605%, on 168,889 volume. The average volume for the last 3 months is 55,944 and the stock's 52-week low/high is $0.27000001/$0.800000011.

Airbnb Inc. (ABNB)

Kiplinger Today, The Street, InvestorPlace, Schaeffer's, MarketBeat, Daily Trade Alert, The Online Investor, Trades Of The Day, Top Pros' Top Picks, Zacks, StreetInsider, MarketClub Analysis, Investopedia and CNBC Breaking News reported earlier on Airbnb Inc. (ABNB), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

To view the full article, visit https://ibn.fm/OkfEW

Airbnb is an American company that operates an online marketplace for lodging, primarily homestays for vacation rentals, and tourism activities. Based in San Francisco, California, the platform is accessible via website and mobile app. Airbnb does not own any of the listed properties; instead, it profits by receiving commission from each booking. The company was founded in 2008 by Brian Chesky, Nathan Blecharczyk and Joe Gebbia. Airbnb is a shortened version of its original name, AirBedandBreakfast.com. For more information about the company, visit www.Airbnb.com.

Airbnb Inc. (ABNB), closed Monday’s trading session at $149.94, up 0.180397%, on 6,450,955 volume. The average volume for the last 3 months is 7.71M and the stock's 52-week low/high is $121.50/$219.940002.

The QualityStocks Company Corner

Sigma Labs Inc. (NASDAQ: SGLB)

The QualityStocks Daily Newsletter would like to spotlight Sigma Labs Inc. (SGLB).

Sigma Labs (NASDAQ: SGLB), a leading developer of quality assurance software for the commercial 3D metal printing industry, announced that it has been named to the Russell Microcap(R) Index effective today with the annual Russell U.S. Indexes reconstitution. The announcement noted that membership in the Russell Microcap Index also entails automatic inclusion in other appropriate growth and value style indexes. Investment managers and institutional investors commonly use Russell US Indexes as the basis for index funds and as benchmarks for active investment strategies; in fact, an estimated $9 trillion in assets are benchmarked against Russell US Indexes. FTSE Russell, a leading global index provider, determines membership for its indexes every year; the determination is made primarily through objective market capitalization ranking, and style attributes. “The inclusion of Sigma Labs to the Russell Microcap Index will enable greater access and visibility to institutional investors and investment managers," said Sigma Labs president and CEO Mark K. Ruport in the press release. “We are moving forward on multiple fronts on our internal roadmap with a strengthened balance sheet, a growing customer base, and a robust outlook for the 3D metal printing market. Our team's hard work and dedication have brought us to this point, and I believe we are well-positioned to continue building momentum and drive value as the market accelerates." To view the full press release, visit https://ibn.fm/djEnx

Sigma Labs Inc. (SGLB) is the only provider of in-process quality-assurance software to the commercial 3D printing metal industry that enables operators of machines making 3D metal parts to offset emerging quality problems, sustain part quality, and avoid rejects. Sigma’s software is the singular solution that enables both real-time, in-process detection of quality control manufacturing irregularities for critical metal parts and then provides the operator the actionable information needed to adjust and mitigate the developing anomaly. Sigma Labs’ software represents a paradigm shift in the quality control process for the manufacture of 3D printed metal components. The nascent 3D metal printing industry is on the verge of radically altering the speed and technical complexity of manufactured parts. Further, it makes possible just-in-time availability of critical components – all at reduced cost, time, waste and weight. 3D printing, heralded as the fourth industrial revolution in manufacturing, will only truly surpass traditional techniques when the additive manufacturing industry moves from “post process” quality control to “in process” quality assurance.

For the industry to move from prototype manufacturing of critical components to economically viable commercial production, the 3D metal printing industry must find ways to dramatically increase production speed and quality yields, and to dramatically decrease the excessive cost of quality control. To achieve these prerequisites and move 3D metal printing into the mainstream, parts must be inspected and certified during the manufacturing process rather than after. Parts in the production process that are developing signs of quality control problems must be identified in real-time and alerts must be issued. The problem, along with the solution, must then be communicated to the machine operator to implement repairs.

Revolutionizing Additive Manufacturing

Sigma Labs, with its PrintRite3D® brand, has established a new benchmark in the development and commercialization of real-time computer aided inspection (“CAI”) solutions. Sigma Labs resolves the major roadblocks and costly quality control challenges that impede the 3D manufacture of precision metal parts. The company’s breakthrough computer-aided software product revolutionizes commercial additive manufacturing, enabling non-destructive quality assurance during production, uniquely allowing errors to be corrected in real-time.

Sigma Labs was founded in 2010 by a team of Los Alamos National Labs scientists and engineers to develop and commercially license advanced metallurgical products for the military ordinance, dental implants, and then for additive manufacturing (3D printing). After assessing 3D metal printing technology and the costly, inconsistent quality control issues, Sigma Labs concluded that the enormous potential of 3D metal printing could only scale up if in-process quality-assurance tools were developed to observe, manage and control the manufacturing complexities in such a manner that reliability and repeatability of very high precision quality metal parts could be achieved in the process. Sigma Labs’ patented and third-party validated software has achieved these objectives and now delivers the critical elements needed to unleash the promise of 3D metal printing.

Sigma Labs’ products and services are engineered, manufactured and qualified for use in the highly demanding and hyper precise production environments of the aerospace, defense, transportation, oil and gas, biomedical and other precision-dependent industries.

The Challenge

Additive metal manufacturing combines multiple processes and parts into one single 3D printed part. Due to variances in the additive manufacturing process, parts of consistent quality currently can’t be reliably produced in either large or small quantities without substantial postproduction inspection and rejection costs. Parts are inspected after production using CT scans and other means, so the manufacturer doesn’t know until the very end which of the finished parts meet design specifications. This means lost time, lost profits and inability to economically scale up production.

Innovative Approach

Sigma Labs solves this problem with its patented, in-process quality control technology that informs operators and engineers how to improve both the manufacturing process and quality by capturing meaningful data about inconsistencies in real-time. Sigma Labs is also partnering with OEMs, working toward the visionary introduction of revolutionary closed-loop control that will bypass the machine operator and automatically make in process corrections by reducing machine variations.

Sigma Labs’ next generation technology gives manufacturers the ability to make fast, virtual real-time adjustments so that each finished part is uniform and within critical specifications, thereby improving production quality, decreasing end-users’ risks and waste, and increasing profits and speed to market. Sigma Labs’ PrintRite3D® IPQA Software monitors and assesses the quality of each production part in the 3D additive manufacturing process – layer by layer, and in real-time. This has never been available until now.

Sigma Labs maintains a strong intellectual property portfolio consisting of trade secrets, process know-how and 34 patents either granted, pending or awaiting pre-publication around the globe. These patents encompass the fundamental technologies underlying Sigma Labs’ melt pool process control, data analytics, anomaly detection, signature identification, and future “closed-loop control” of 3D metal printing.

Market Opportunity

Providing advanced quality assurance software to the commercial 3D printing industry is currently a $1.4 billion addressable market expected to grow to $3.9 billion by 2023. Integrating Sigma Labs’ groundbreaking software helps arm the industry with a necessary catalyst to help enable and optimize the fourth industrial revolution in manufacturing.

Sigma Labs’ global client base includes 23 installations across 19 different users. Tier-1 OEM enterprises and end-users such as Siemens, Honeywell, Pratt & Whitney and others are currently evaluating PrintRite3D® for production lines.

Management Team

John Rice, CEO and chairman of the board of directors, has extensive experience as a CEO, lead negotiator, turnaround expert, business financier and crisis management executive/consultant. Prior to becoming chair and CEO of Sigma Labs, he was the CEO of a successful turn-around of a Coca-Cola Bottling Company. Rice has led a variety of companies in diverse business sectors and worked on a host of products and technologies including design and manufacture of high-end jet engine test equipment for the U.S. Airforce, chaff dispensers for F16s, software for modeling naval exercises, software for controlling warehouse distribution systems, medical radioisotopes, cancer detection, and cybersecurity. He is an honor’s graduate of Harvard College.

Darren Beckett, CTO, has over 20 years of experience in the semiconductor industry, including Intel Corporation, where he held various technical and managerial positions. His expertise in process engineering for advanced manufacturing technology includes statistical process control for fabrication of semiconductor devices.

CFO Frank D. Orzechowski also serves as treasurer, principal accounting officer, principal financial officer and corporate secretary. He has more than 30 years of distinguished financial and operational experience. Orzechowski began his career at Coopers & Lybrand in 1982, received his CPA certification in 1984, and received his Bachelor of Science in Business Administration with a major in accounting from Georgetown University in 1982.

Ronald Fisher, vice president of business development, is leading the commercialization of PrintRite3D® 5.0. Fisher is a mechanical engineer with hands-on experience in quality, manufacturing and product development. He has distinguished himself as a lead sales and marketing officer as well as a chief operating officer most recently before joining Sigma in technology startup that grew from market entry to successful exit by merger-acquisition.

Sigma Labs Inc. (SGLB), closed Monday’s trading session at $4.03, off by 3.3573%, on 131,159 volume. The average volume for the last 3 months is 420,534 and the stock's 52-week low/high is $1.95000004/$9.75.

Recent News

Net Element (NASDAQ: NETE)

The QualityStocks Daily Newsletter would like to spotlight Net Element (NETE).

Electric cars have been dubbed the next frontier of vehicular travel as countries around the world scramble to cut their carbon emissions in a bid to curb climate change. Instead of an internal combustion engine, electric vehicles (“EVs”) use a rechargeable lithium-ion battery coupled with an electric motor for power. Despite their obvious environmental benefits, not everyone is sold on electric vehicles, and slow charging rates are partly to blame. Unlike filling up a petrol or diesel-powered car, which can be done in as little as five minutes, electric vehicles take quite a while to recharge. Even with fast charging infrastructure, it will take a driver at least 30 minutes to charge an electric vehicle to 80%. For those who own a Tesla, one of the company’s supercharging stations can add up to 200 miles of range in 15 minutes. Although that’s pretty fast, it still pales in comparison to the relative ease and speed of filling a tank with gas and hitting the road without having to worry about where the next charging station is. As new players such as Net Element (NASDAQ: NETE) join the electric vehicle sector, superior solutions are likely to be found to address many of the issues that have been slowing the uptake of these eco-friendly vehicles.

On June 15, 2020, Net Element announced its entry into a binding letter of intent to merge with privately-held Mullen Technologies Inc., a Southern California-based electric vehicle company, in a stock-for-stock reverse merger in which Mullen’s stockholders will receive the majority of the outstanding stock in the post-merger company. The proposed merger is currently pending the execution of a definitive agreement, shareholder vote and regulatory approval.

Net Element Inc. (NASDAQ: NETE) is a global financial technology and value-added solutions group that supports electronic payments acceptance in an omni-channel environment spanning across point-of-sale, e-commerce and mobile devices. The company operates a payments-as-a-service transactional model and value-added services platform for small to medium enterprises in the U.S. and selected emerging markets.

Net Element believes the future of global commerce is being revolutionized as consumers quickly migrate toward omni-channel shopping utilizing mobile devices, desktop, and online services. The company’s all-in-one payment solutions support and unify a whole range of applications through a single, robust platform, allowing global onboarding and support for multiple payment methods.

Net Element has also launched a blockchain-focused business unit that will develop and deploy blockchain technology-based solutions. Net Element expects the new division to create a decentralized crypto-based ecosystem that will act as a framework for an unlimited number of value-added services, connecting merchants and consumers in a seamless, economically efficient transaction. This new business unit intends to also identify and invest in unique projects that decentralize and disrupt the payment processing industry by combining blockchain technology and real-world applications with talented development teams, strong fundamentals and addressable markets large in size.

“We believe that we’re at the dawn of a new evolution where additional digital payment methods are being introduced,” Net Element chairman and CEO Oleg Firer, says. “Introduction of our division focused on blockchain as part of the NASDAQ-listed entity will add transparency and compliance assurance to our investors as well as provide access to deploy value-added services to over 20 million electronic commerce clients that are currently part of Net Element’s growing network.”

Net Element clients are treated to customized solutions that provide the flexibility needed to keep up with customers. Among the services offered are mobile payment apps that accept payments anywhere, anytime; cloud-based solutions built to increase productivity and enhance revenue for clients and partners; marketing solutions that turn lookers into buyers; and business analytics that make it easy for clients to monitor business metrics, engage with customers and compare the competition. Its multi-channel platform combines e-commerce, offline, point-of-sale, comprehensive back office tools, mobile point-of-sale, credit scoring and customer interaction in one powerful platform-as-a-service technology.

Net Element owns and operates a global mobile payments and transactional processing provider, TOT Group, Inc., with the following subsidiaries:

  • Unified Payments – An award-winning, customized mobile billing and payments solution, recognized by Inc. Magazine as the No. 1 Fastest Growing Company in America in 2012.
  • Aptito – A next-generation, all-in-one, cloud-based restaurant management and point-of-sale payments platform using wireless technology.
  • Payonline – A fully integrated, processor agnostic electronic commerce platform.

Net Element is ranked on Deloitte’s Technology Fast 500™ list of North America’s 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in both 2017 and 2018, during which the company grew 190 percent and 183 percent, respectively. The company credits its progression to organic growth in its North America Transactions Segment, specifically the success of its Unified Payments brand, which focuses on value-added payment acceptance solutions for small to medium enterprises in the United States.

Net Element was also listed among South Florida Business Journal’s 2016 fastest growing technology companies.

Leveraging its suite of application performing interfaces (APIs) and connectors, Net Element powers commerce for businesses of all sizes through multi-channel platforms, all-in-one digital solutions, and end-to-end encryption of cardholder data utilizing tamper resistant hardware that ensures integrity and simplifies security.

Leading this innovation is chairman and CEO Oleg Firer, who is responsible for the overall vision, strategy and execution of the company’s mission of powering global commerce. He is joined by CFO Jeffrey Ginsburg, CPA, and Steven Wolberg, the company’s chief legal officer and secretary. Each corporate officer brings a unique blend of leadership, vision, experience and creative energy to the company.

From mobile payments and value-added transactional innovations like Aptito to e-commerce and retail payment transaction processing brands like Payonline and Unified Payments, Net Element is transforming the online and mobile experience.

Net Element (NETE), closed Monday’s trading session at $11.65, off by 2.0185%, on 117,908 volume. The average volume for the last 3 months is 143,504 and the stock's 52-week low/high is $5.57000017/$20.0783996.

Recent News

Sanwire Corp. (SNWR)

The QualityStocks Daily Newsletter would like to spotlight Sanwire Corp. (SNWR).

Sanwire (OTC: SNWR), a diversified company with a focus on technologies for the entertainment industry, together with its 100% wholly owned subsidiary, Intercept Music Inc., today announced that one of their artist's songs was used in a TikTok that has over 105,000,000 views and 8,600,00 likes. According to the update, Will Gittens was introduced to Billy Moss at Diamond Empire Records where Moss, a RIAA Multi-Platinum Grammy nominated producer with a keen eye for new talent, is the director of operations. After listening to the song Zodiac, produced by JR Gittens, Will's brother, Moss put a deal together with CEO of Diamond Empire Productions, Rob Diamond, to add Will Gittens and Zodiac to their roster. A contestant on Season 6 of The Voice, Will Gittens is a multi-instrumentalist, singer and social media influencer. His new song, Zodiac, was recently used in a TikTok by well-known actor and star Jason Statham, where the video immediately went viral. "We are incredibly proud of Will and his great success with Zodiac," said Tod Turner, president of Intercept. "The success of this video just goes to show you what the proper talent, management, distribution, marketing, and a little luck can do. Will has only been with the Intercept team for a little over two months and has already had amazing results." To view the full press release, visit https://ibn.fm/Y1xVw

Sanwire Corp. (SNWR) is a diversified company currently focused on technologies for the music industry. The company specializes in locating unique opportunities in fragmented markets and implementing its aggregated technologies to consolidate distinct services into unified platforms of delivery. Sanwire is currently focusing these efforts on advanced entertainment technologies.

Founded in 1997 and based out of Las Vegas, Nevada, Sanwire has operated and sold several subsidiaries as it has worked in various industry segments, including Sanwire Software Inc., Bullmoose Mines Ltd. and Squeeze Report Inc. Currently, there are two new holdings that were added to the company’s portfolio through two recent acquisitions, including Intercept Music Inc. in March 2020 and the Art is War Record Label in June 2020.

Intercept Music Inc. – Artist-Focused Services

Intercept Music Inc. is an entertainment technology company offering a unique suite of artist-focused services that are specifically designed to meet the needs of recording artists. Intercept’s proprietary online platform is dedicated to helping millions of global independent artists effectively promote their music and distribute it worldwide to hundreds of digital stores and every major streaming platform, including Spotify, Apple Music, Amazon Music, Pandora and Google Music.

With Intercept Music, recording artists have all the tools needed to market, promote and sell their music online and through social media. Comprehensive reporting allows artists to track the fan response to their releases, all the way down to individual music tracks.

There are three foundations of Intercept Music’s product offering:

  • Its music distribution platform that is well augmented via the company’s partnership with InGrooves, a wholly owned subsidiary of Universal Music, which is arguably one of the largest music companies in the world.
  • Its social media system, which is tailored to work the way artists use social media to promote their music and engage with their fans. The scheduling system integrates artists’ profiles across multiple social networking sites (Facebook, Twitter, Instagram and YouTube) to facilitate new audience sampling, fan development and the ability for music to be previewed and purchased.
  • The third is represented by the team of developers that brings a unique combination of deep technical expertise (in products like Skype), a team of well-accomplished executives and what the company calls Brand Ambassadors – senior reps from multiple genres who have helped artists earn over 100 Grammys.

Intercept Music is the confluence of technology and this music expertise.

The company currently markets three plans to its clients, with each offering different distribution and royalty options, as well as various marketing and reporting options. The plans are described below:

  • Intercept Distro is a basic plan for self-service music distribution with royalty collection. Artists keep 100% of the royalties while receiving unlimited releases and full analytics with reporting.
  • Intercept Artist includes all of the benefits of the basic Distro plan with added emphasis on social marketing and distribution for emerging artists. With this plan, artists receive scheduled and ad-hoc posting, social media reporting, reusable content libraries and access to other valuable features.
  • Intercept PLUS is available by invite only and is for established artists looking for a complete suite of marketing, distribution and monetization services. The PLUS plan includes everything available through the Distro and Artist plans, as well as offering a dedicated service representative, a branded online store, on-demand merchandise, additional marketing, YouTube monetization and other pro features.

Intercept PLUS is the flagship plan. Artists of this caliber often do $3-$10k/month in merchandise sales alone, at 50%+ profit. Intercept is responsible for marketing to the fan base through its social media system and shares in the profits generated. The stores are managed by intercept so both top-line revenues and bottom-line profits flow through Intercept.

Intercept Music has partnered with Ingrooves Music Group, the largest online music distribution company in the world, for worldwide distribution to streaming services and leading stores. Completing more than 50 billion transactions weekly across over 150 countries, Ingrooves supplies music to leading streaming music platforms and lists some of the world’s largest and most reputable music labels among its clients. The partnership allows Intercept Music and its clients to reach a much wider audience and start earning revenue as soon as possible by leveraging Ingrooves’ quality control systems and direct relationships with leading music streaming services.

Physical Distribution Options for Intercept Music Clients

In a press release on June 25, 2020, Intercept Music announced that it would be offering artists physical distribution through major retailers such as Amazon, FYE and Walmart (http://nnw.fm/NSrbE). The physical distribution will consist of CDs and vinyl and will serve as a supplement to the online streaming platform access provided by the company to represented artists.

“In the current climate, artists can’t play shows or otherwise engage in public at all, so they’re focusing on all other opportunities to bring in revenue,” Intercept Music President Tod Turner stated in a news release. “Our only priority is to help artists monetize music in every way, and with physical distribution added to the mix, we’re leaving no stone unturned in helping artists to earn money from their creative output.”

Creation of Preferred Stock

On June 29, 2020, Sanwire CEO Christopher Whitcomb announced that the company would be filing certificates of designation with the Nevada Secretary of State for its Series A, B and C preferred stock (http://nnw.fm/svrQt).

Speaking about this designation in a news release, Whitcomb stated, “Our paramount goal is to maintain a balanced approach between future investments and shareholder value while minimizing shareholder dilution. The effective utilization of preferred stock ensures our company can grow with the least amount of shareholder dilution.”

Sanwire is leveraging a multi-dimensional strategy that includes additional acquisitions, attracting investors and enhancing the current balance sheet while minimizing dilution for shareholders. A primary goal of these efforts is to support Intercept’s ongoing operations.

Financial Highlights

For the fiscal quarter ended June 30, 2020, Sanwire announced significant revenue growth related to the acquisitions of Intercept Music and Art is War Records. Since acquiring Intercept Music in March and Art is War Records in June, Sanwire’s revenue has increased by approximately 300% (http://nnw.fm/j0S0j). Sanwire attributes the increase in revenue to Intercept Music’s customer acquisition and the release of its PLUS plan.

For the third quarter, revenue is expected to continue an upward climb, owing largely to physical distribution plans and a rising number of PLUS subscribers. The company’s acquisition of Art is War Records is also expected to fuel this growth.

Management

Christopher M. Whitcomb is the current CEO of Sanwire Corp. and Intercept Music Inc. He is a CPA in the state of California, holding bachelor’s degrees in accounting, corporate finance and business management with a focus on real estate. A seasoned executive, his business ventures are always strongly focused on the development and financing of companies.

Whitcomb worked alongside Ralph Tashjian at SMC Entertainment Inc. and Digital Music Universe. They are currently working together again following Sanwire’s acquisition of Intercept Music, which was founded by Tashjian.

Sanwire Corp. (SNWR), closed Monday’s trading session at $0.00795, up 15.2174%, on 223,000 volume. The average volume for the last 3 months is 957,879 and the stock's 52-week low/high is $0.005499999/$0.048399999.

Recent News

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF)

The QualityStocks Daily Newsletter would like to spotlight Plus Products Inc. (CSE: PLUS) (OTC: PLPRF).

Plus Products (CSE: PLUS) (OTCQX: PLPRF), a cannabis- and hemp-branded products company, announced that it has filed an early warning report on behalf of Matt Schmidt in accordance with the National Instrument 62-103. The report contains information regarding Schmidt’s holdings in the company, specifically regarding the acquisition of class B common shares that were issued pursuant to restricted stock units. According to the announcement, Schmidt now owns 25,100,000 class B subordinate voting shares and 100 common shares, which represents 100% of the issued and outstanding class B subordinate voting shares. “Mr. Schmidt’s effective economic and voting interests in the company are equivalent to the 125,700 common shares, which his class B subordinate voting shares are convertible into on a 200-to-1 basis (and including his current common share holdings), representing a 0.26% interest in the overall voting shares of the Issuer,” the press release stated.“Further, Mr. Schmidt has previously entered into an agreement with the company such that in the case of any shareholder action that would entitle holders of class B subordinate voting shares to vote as a separate class or series, and the requisite majority of holders of common shares have approved such action, Mr. Schmidt will: (a) vote all of his class B subordinate voting shares in favor of such shareholder action and (b) execute and deliver all resolutions, consents and other instruments, related to his class B subordinate voting share holdings, in favor of such shareholder action.” To view the full press release, visit https://ibn.fm/OCKAm

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF) is a branded cannabis-infused products manufacturer of edibles created to support a healthy and active lifestyle. Headquartered in San Mateo, California, PLUS™ concentrates on producing edibles using extracts to ensure compliant, dosable and delicious products that provide a consistent cannabis experience.

First introduced to the market in 2015 to rave reviews, PLUS™ is now one of the top best-selling edible brands in California. PLUS™ operates through a wholly owned subsidiary, Carberry, and has four cannabis-infused gummy candy SKUs (in addition to limited edition SKUs), that are currently sold in over 200 licensed dispensaries and delivery services. All products under the PLUS™ brand are produced in the company’s 12,000-square-foot food-safe cannabis manufacturing facility in Adelanto, California.

PLUS Products shares are currently listed on the Canadian Securities Exchange. PLUS™ raised CAD$20 million through the offering, for which the lead underwriters were PI Financial and Canaccord Genuity. The company intends to use a portion of the IPO proceeds to fund rapid product capacity expansion, factory automation, working capital and new product development.

Operating in the largest adult-use recreational market in the U.S., PLUS Products holds a temporary manufacturing license in California and was one of the first brands to bring fully compliant products to the legal market. California legalized adult use recreational sales on Jan. 1, 2018, and industry analysts expect edible sales there will continue to amass enviable revenues. According to BDS Analytics, edibles made up 18 percent of marijuana retail sales in February 2018 across licensed retailers in California, with PLUS™ products ranking in the Top 10 of edible brands by retail dollar sales.

During the first half of 2018, PLUS Products generated US$2.45 million in sales, a marked improvement over 2017’s US$1.07 million in sales. The company’s established cannabis products are not only compliant with state laws, they are proving to be extremely popular with consumers. Among the PLUS™ product brands are:

  • Blackberry & Lemon RESTORE, an infusion of carefully dosed cannabis with a 9:1 THC to CBD per gummy.
  • Sour Watermelon UPLIFT, a low-calorie gummy crafted from carefully dosed cannabis with an infusion of 5mg THC per gummy.
  • Pineapple & Coconut CBD RELIEF, a tropical flavor gummy made from pure cannabis-derived CBD that is low-calorie, gluten-free and made with kosher ingredients.
  • Sour Blueberry CREATE, a low-calorie gummy infused with hybrid flower containing 5 mg THC.
  • Limited Edition Rose & Vanilla, available at select locations during Winter 2018, these gummies are crafted with 60 mg THC/30 mg CBD per tin.
  • Limited Edition RAINBOW SORBET gummies was created to celebrate Pride during Spring 2018 with a portion of each purchase donated to The Trevor Project, a confidential suicide hotline for LGBT youth.

“We are extremely proud of the products PLUS has brought to market,” remarked Jake Heimark, CEO and cofounder in a statement. “We’ve quickly grown into one of the leading edible brands in California. With the proceeds of this round, we will continue to further our mission: to make cannabis safe and approachable for all types of consumers.”

The PLUS™ team believes that everyone deserves access to consistent, dosable and delicious cannabis products and strives to make that happen. Producing the best infused products at scale requires thoughtful collaboration among experts in many fields. At PLUS™, our team is comprised of Chefs, Chemists, Food Manufacturing Experts, Engineers, Machinists, Visionaries, Creatives, Strategists and others.

Plus Products Inc. (PLPRF), closed Monday’s trading session at $0.398, off by 0.350526%, on 39,810 volume. The average volume for the last 3 months is 82,553 and the stock's 52-week low/high is $0.324999988/$1.14999997.

Recent News

TAAT Lifestyle & Wellness Ltd. (CSE: TAAT) (OTCQB: TOBAF)

The QualityStocks Daily Newsletter would like to spotlight TAAT Lifestyle & Wellness Ltd. (CSE: TAAT) (OTCQB: TOBAF).

TAAT(TM) Global Alternatives (CSE: TAAT) (OTCQX: TOBAF) (FRANKFURT: 2TP) shipped an initial purchase order to a Peach State Distributor (“PSD”) in Georgia last week; the entire shipment of 15 TAAT(TM) master cases, which was delivered on June 24, 2021, was sold out before the product arrived. The purchase order was part of a company initiative to test the state of Georgia as the next market for a full-scale launch of TAAT, which is an alternative to tobacco cigarettes. The announcement noted the move complements TAAT’s presence in more than 250 retailers in the state of Ohio. The PSD convenience wholesaler has a 1,200-store network, with 90% of its stores located in Georgia; other locations are in North Carolina, South Carolina and Alabama. To view the full press release, visit https://ibn.fm/9x8r9

TAAT Lifestyle & Wellness Ltd. (CSE: TAAT) (OTCQB: TOBAF) is a life sciences company dedicated to giving legal-aged smokers the choice to keep the smoking experience that they enjoy with no nicotine and no tobacco.

The key players of TAAT Lifestyle & Wellness are from leading tobacco brands. They are guiding the mission with the company’s proprietary product, TAAT(TM), which uses the company’s proprietary Beyond Tobacco(TM) base material. The base material undergoes a 14-step process to taste and smell just like tobacco and uses a patent-pending refinement technique.

This provides the company with unique opportunities on the global tobacco market, which was estimated at $849 billion in 2019, with approximately 1.3 billion people using tobacco in some form worldwide (https://nnw.fm/bvKFL).

TAAT Lifestyle & Wellness was founded in 2006 and is headquartered in Vancouver, Canada, with operations in Las Vegas, Nevada.

TAAT(TM)

TAAT is a smokable alternative to tobacco cigarettes using the Beyond Tobacco base material, which contains zero tobacco and zero nicotine. The current TAAT offering comes in three varieties: Original, Smooth and Menthol, which were launched during Q4 2020 in Ohio. The company’s Ohio tobacco wholesaler also distributes for major tobacco industry names such as Altria, RJ Reynolds (a subsidiary of British American Tobacco) and ITG.

The TAAT Beyond Tobacco experience was created to replicate the sensory elements of smoking a tobacco cigarette. Market testing in California and Nevada reached a consensus that TAAT products offered no significant differences in experience when compared to tobacco cigarettes, in terms of the following aspects:

  • Visual – the nearly identical product packaging and enhanced smoke volume
  • Auditory – the “crackling” sound of the base material when it is ignited
  • Smell – when burning, TAAT emits a tobacco-like scent
  • Taste – the patent-pending Beyond Tobacco base material undergoes a refinement process that creates a tobacco-like taste
  • Touch – TAAT satisfies the “hand-to-mouth” fixation and motor habits, such as flicking ashes

TAAT Beyond Tobacco Targeting Current Smokers

TAAT Lifestyle & Wellness is currently targeting the market of legal-aged smokers with its proprietary product. The company aims “not to create a new problem, but to solve an existing one.” TAAT Lifestyle & Wellness offers a non-addictive alternative to tobacco, with several competitive advantages making it a promising option on the United States market, such as:

  • Price – TAAT can be offered at a lower price than competing products in the tobacco category, which adds to the propositioned value for current legal-aged smokers.
  • Experience – TAAT appeals to current smokers who wish to give up the tobacco and nicotine but keep the smoking experience they enjoy.
  • Branding/Packaging – TAAT is American-grown and American-made, with its Beyond Tobacco base material serving as a legacy to the combustible tobacco products.

The current alternatives to cigarette smoking do not offer a comparable experience. Previously marketed products, like vaping, proved difficult for some legal-aged smokers to adopt, as the experience was too different from traditional cigarettes.

Market Outlook

In 2016, the United States tobacco market was valued at over $100 billion, a number that’s expected to grow over the next decade (https://nnw.fm/yd8oP). In terms of volume, over 215 billion cigarettes were sold to roughly 34 million adults in the United States in 2018. These numbers represent almost 14% of the adult population. Of those, almost two-thirds smoked more than 15 cigarettes in one day. A standard pack is comprised of 20 cigarettes.

The company’s Beyond Tobacco, as a non-tobacco product, has a price-driven consumer advantage in many states. While state taxes on traditional cigarettes vary, most tend to average around $1.82 per pack. Washington D.C. is on the higher end of the tax spectrum at $4.50 per pack, whereas Missouri is only $0.17 per pack (https://nnw.fm/D3WnT).

TAAT Lifestyle & Wellness estimates that, if one pack of TAAT Beyond Tobacco was sold at 20% of all United States tobacco points of sale, the product would capture 0.25% of the market, the equivalent of approximately 2.7 million cartons of cigarettes per year.

Management Team

Setti Coscarella is the Chief Executive Officer of TAAT Lifestyle & Wellness Ltd. He is experienced in investment banking, private equity and entrepreneurship. In 2017, Mr. Coscarella was the lead strategist for Reduced-Risk Products at Philip Morris International. While there, he worked with thousands of smokers to better understand how to position smoking alternatives, developing programs that could help smokers convert to reduced-risk products. Mr. Coscarella holds an MBA from the Schulich School of Business, specializing in finance, marketing and corporate strategy. He also has a Bachelor of Science in mathematics and physics from the University of Toronto.

Tim Corkum is the company’s Chief Revenue Officer. He has a lengthy history in the tobacco industry, having served 21 years at Philip Morris International. Mr. Corkum has experience leading the international commercialization of combustible cigarettes and working on reduced-risk product offerings. During his 21-year tenure, he held senior positions in business development, sales strategy, key account management and corporate affairs. He holds a BA from Carleton University with a concentration in law.

Joe Deighan is Founder of TAAT Lifestyle & Wellness and oversees research and development. He is the founder of vape liquid ‘JJuice’, created in 2012. JJuice was distributed across all of the United States and in 26 other countries, alongside the private label production that was done for other brands. Mr. Deighan sold JJuice in a cash deal that was valued at over $800,000 in 2017. He currently handles all R&D and production for Beyond Tobacco, knowing the product better than anyone else in the company.

TAAT Lifestyle & Wellness Ltd. (TOBAF), closed Monday’s trading session at $2.41, off by 5.4902%, on 117,829 volume. The average volume for the last 3 months is 158,585 and the stock's 52-week low/high is $0.100000001/$4.73999977.

Recent News

Sustainable Green Team Ltd. (SGTM)

The QualityStocks Daily Newsletter would like to spotlight Sustainable Green Team Ltd. (SGTM).

  • SGTM released Q1-2021 results showing $9,291,931 in revenue, $1,400,720 in gross profit, $41,477,914 in total assets
  • QoQ growth includes 16.7% revenue increase, 8.6% gross profit increase
  • 2020 was record-breaking year: 794% revenue, 4,817% gross profit growth in Q1 and Q2 compared to all of 2019

Sustainable Green Team (OTC: SGTM), a leading provider of environmentally beneficial solutions for tree and storm waste disposal, recently announced Q1-2021 financial results that indicate the company may surpass its record-breaking 2020 financial performance (https://ibn.fm/1Q9cw).

Sustainable Green Team Ltd. (OTC: SGTM), through its subsidiaries, including National Storm Recovery LLC (DBA Central Florida Arbor Care and Mulch Manufacturing Inc.), provides tree services, debris hauling, removal and bio-mass recycling, manufacturing, packaging and sales of next-generation mulch products. The company’s primary corporate objective is to provide a solution for the treatment and handling of tree debris that is historically sent to local landfills and disposal sites, creating an environmental burden and pressure on disposal sites around the nation.

Environmentally Friendly

SGTM and the solutions provided by its Sustainable Green Team are founded in sustainability. The company’s vertically integrated operations begin with the collection of tree debris through its tree services division and collection sites. Tree bio-mass is then moved through the processing division for recycling and manufacturing into a variety of organic, attractive, next-generation mulch products to be packaged and sold to retailers, landscapers, installers and garden centers.

The company’s solutions create a synergistic and environmentally beneficial solution to tree and storm waste disposal that historically has created an environmental burden on landfills and disposal sites around the nation.

SGTM’s customers include governmental, residential and commercial customers and now big box retailers. The company is headquartered in Florida.

Strategic Acquisition

SGTM in February 2020 acquired 35-year-old industry leader and innovator Mulch Manufacturing Inc., an Ohio corporation. Structured as a share exchange, this strategic partnership provides SGTM with a significantly larger footprint in the mulch industry.

The acquisition includes Mulch Manufacturing’s national and international distribution agreements, an increase in production and packaging capacity, and its sales contracts with numerous big box retailers. Mulch Manufacturing includes mulch production, sawmill operation, Natures Reflections colorant manufacturing and equipment manufacturing.

Next-Gen Products

SGTM’s vision and commitment to the environment is paired with Mulch Manufacturing’s revolutionary “next-generation” mulch product, Nature’s Reflection’s Softscape®.

Softscape mulch products, created from natural forest products, are color-enhanced with environmentally safe colorants to provide four-year color retention and are free from contaminants. Safe for people and pets, Softscape allows water and air to penetrate soil and roots, which is vital to plant health and growth.

Expansion Plans

SGTM plans to expand its operations through a combination of organic growth, through its partnership with a nationally recognized waste disposal company, and through strategic acquisitions that are both accretive to earnings and positioned for rapid growth from the resulting synergistic opportunities identified.

The company has received final zoning approval for its 100-acre site, located in Lake County, Astatula, Florida, which will serve as its flagship tree debris collection site. The facility will also house the company’s mulch manufacturing, soil composting and production bagging. This prime location includes a 5,000-square-foot building that contains warehouse and office space. The 100-acre property can accommodate millions of cubic yards of organic debris and will allow SGTM’s debris hauling division to realize significant savings on its transportation costs.

SGTM has chosen as its new headquarters the 100,000-square-foot Mulch Manufacturing building in Jacksonville, Florida. The facility comprises centralized operations of Mulch Manufacturing Inc. and National Storm Recovery LLC and has ample room to expand as needed.

Leadership

SGTM’s leadership team boasts more than 40 years of next-level experience with mulch manufacturing, treating and caring for trees. This team is guided by a roster of highly qualified professionals:

  • Tony Raynor, Chief Executive Officer
  • Edward Lee, Chief Operating Officer
  • Ralph Spencer, Director of Business Development, Strategic Acquisitions
  • Steve Ogden, ISA-Certified Arborist
  • Rick Starcher, Master Chemist
  • Peder K. Davisson, Esq., Corporate/Securities Counsel

Sustainable Green Team Ltd. (OTC: SGTM), closed Monday’s trading session at $1.245, off by 12.6316%, on 270 volume. The average volume for the last 3 months is 1,100 and the stock's 52-week low/high is $0.200000002/$7.00.

Recent News

GoldHaven Resources Corp. (CSE: GOH) (OTCQB: GHVNF)

The QualityStocks Daily Newsletter would like to spotlight GoldHaven Resources Corp. (CSE: GOH) (OTCQB: GHVNF).

GoldHaven Resources (CSE: GOH) (OTCQB: GHVNF) (FSE: 4QS), a Canada-based company engaged in the business of acquiring and exploring mineral resource properties, today announced its entry into an earn-in agreement. Under the agreement, GoldHaven may earn a 100% interest in the 4,190-hectare Smoke Mountain copper-gold property located in central British Columbia approximately 60 kilometers southwest of Houston and 23 km north-northwest of Imperial Metals Corporation's copper-molybdenum-silver Huckleberry Mine. Per the update, the property is accessible via a series of gravel forest service roads off Highway 16. “The Smoke Mountain Project provides GoldHaven's shareholders with access to a gold-copper endowed project in a sought-after metal belt in British Columbia,” said Daniel Schieber, GoldHaven's CEO. “This area has seen a significant amount of discovery, most recently Sun Summit's (SMN.V) Buck property and Equity Metals' (EQTY.V) Silver Queen have been delivering high grade gold and silver results. We are on a very prospective belt, and this will ensure that GoldHaven can provide results to shareholders year-round.” To view the full press release, visit https://ibn.fm/gEhGd

GoldHaven Resources Corp. (CSE: GOH) (OTCQB: GHVNF) (formerly Altum Resources Corp.), a Canada-based company engaged in the business of acquiring and exploring mineral resource properties, recently announced its entry into agreements to acquire seven advanced gold projects in the Maricunga Gold Belt of Chile that hosts over 100 million ounces of gold within the last 10 years.

Chilean Gold Properties Being Acquired

On April 17, 2020, GoldHaven Resources entered into an agreement to purchase a 100% interest in two gold projects located in the Maricunga Gold Belt of Northern Chile. The first property, Rio Loa, is located 25 kilometers south of Gold Fields Ltd.’s Salares Norte, where, this year, a five-million-ounce discovery was made. The second property, Coya, is located only 10 kilometers east of the Kinross La Coipa open pit mine, which has produced over 7.5 million ounces of gold to date.

Rio Loa Project

Initial geophysical studies of the Rio Loa site have exposed highly anomalous ardennite and lead values, a key characteristic of gold mineralization within silicified resistive bodies. The studies have also produced initial findings which are similar to those seen at contiguous mines, such as Salares Norte (operated by Gold Fields), which has over five million ounces in estimated gold deposits.

The potential economics for the site look particularly promising when taking the unit costs at the neighboring Salares Norte mine into account. Gold Fields has estimated that its production AISC (all-in sustainable costs) will approximate $552 per ounce and have forecast a 2.3-year payback period for its initial investment, assuming a $1,300 per ounce gold price.

Coya Project

The Coya site is located within close proximity to one of the richest and largest epithermal gold and silver districts in Chile and is in close proximity to active mining sites, specifically the La Coipa mine owned by Kinross. A study carried out in 2017-2018 on the Coya site of 796 rock chip samples found favorable gold and silver values, in some cases ranking as high as 764 grams/tonne of gold and 719 grams/tonne of silver – values which are near certain indicators of potential gold and silver deposits. The La Coipa mine (Kinross) has produced over 6.9 million ounces of gold to date.

On August 11, 2020, GoldHaven Resources acquired five potential gold projects in the Maricunga Gold Belt of Northern Chile. The Maricunga hosts discoveries within the last 10 years of over 100 million ounces of gold and over 450 million ounces of silver. These newly acquired properties are in close proximity to seven other mines, which possess an estimated aggregate of 81 million ounces of gold in total reserves.

GoldHaven’s five new projects cover a total area of approximately 22,600 hectares, or 226 square kilometers, located in the northern portion of the Maricunga Belt in proximity to the 5 million-ounce gold equivalent Salares Norte project owned by Gold Fields. Gold Fields announced in April 2020 its intention to proceed with the development of Salares Norte at a cost of $860 million, with a $138 million expenditure budgeted for 2020.

The Maricunga Belt extends approximately 150 kilometers north-south and 30 kilometers east-west, straddling the border between Chile and Argentina. This region hosts known mineral resources of more than 100 million ounces of gold, 450 million ounces of silver and 1.3 billion pounds of copper.

The Maricunga project’s opportunity came about as a result of a $150 million initiative launched by the Chilean Economic Development Agency (“CORFO”), with the objective of encouraging exploration and mining prosperity in Chile and strengthening Chile’s position as a world leader in the sector.

As part of CORFO’s program, a total of $15.3 million was given to private equity fund IMT Exploration to evaluate 403 projects, beginning in 2011. This led to a generative program carried out from 2016 to 2019, resulting in 126 potential epithermal targets from which 57 field evaluations were made. Due diligence work followed on 19 of these. Work programs were then conducted, including geological mapping, rock and soil sampling and TerraSpec (PIMA) analyses on geochemical grids for alteration mapping, and, as a result, the five high-priority Maricunga projects were identified. No drilling has been carried out on any of the Maricunga projects.

Securing Financing for Upcoming Operations

In conjunction with its announcement regarding its acquisition of five Chilean mining interests, GoldHaven Resources also detailed plans for a non-brokered private placement of 11.5 million units at a price of $0.35 per unit, for gross proceeds of $4,025,000. Each unit will consist of one share of the company and one warrant, the latter of which can be exercised to acquire an additional share of the company for a period of 18 months from the date of issuance at a price of $0.50 per share. Net proceeds from the offering are intended to be used to fund general expenses, as well as exploration and drilling of its mineral properties.

Gold Prices Hit Record High in 2020

Gold prices have been on a remarkable run in 2020, breaking above $2,000 per ounce for the first time on record. Having begun the year at $1,515 per ounce, the precious metal has seen a huge surge on the back of widespread economic uncertainty stemming from governments’ worldwide propensity to expand the money supply, from the reduction of the value of the U.S. dollar as expressed by the decrease in the U.S. dollar index, and from the very real economic effects of the COVID-19 pandemic.

Global central banks have carried out 144 interest rate cuts thus far in 2020, reducing rates by a cumulative 5,035 basis points (http://nnw.fm/jzZt0). Meanwhile, the IMF has estimated that global governments have introduced fiscal support measures amounting to over $9 trillion since the start of the pandemic (http://nnw.fm/Or9rI). The resulting weakness in the U.S. dollar and eventual inflationary pressures stemming from these measures has prompted a number of investment banks to boost their near-term outlooks for gold prices, with Bank of America raising its 18-month gold price target to $3,000 per ounce (http://nnw.fm/PQJtc).

Leadership Team

David Smith, President, CEO and Director, has been immersed in the mining industry for the last eight years, working in corporate development and finance. Prior to GoldHaven Resources, Smith cofounded a multifaceted real estate development and sales company, which has now been in operation for over 35 years. He also cofounded two successful environment-focused companies listed on the Toronto Stock Exchange. Both companies were sold independently and returned a significant profit for shareholders.

Darryl Jones, Chief Financial Officer, is a finance executive and CPA with over 30 years of public company and project buildout experience. Most recently, Jones served as the CFO of Lupaka Gold Corp., retiring in June 2018. Prior to that, Jones serves as CFO of Corriente Resources, which was sold to CRCC-Tongguan in May 2010 for C$680 million.

Patrick Burns, VP Exploration and Director, is a Canadian geologist with over 40 years of experience throughout the Caribbean and Central and South America. He played a direct role in the discovery of the Escondida porphyry copper deposit in Chile and has been involved in publicly traded mining companies, predominantly in Chile, for 35 years.

Marla Ritchie, Corporate Secretary, brings over 25 years of experience in public markets to the GoldHaven team. Throughout this time, she has worked as an administrator and corporate secretary specializing in resource-based exploration companies. Currently, Ritchie is the corporate secretary for several companies, including International Tower Hill Mines Ltd. and Trevali Mining Corp.

Gordon Ellis, Director; has over 50 years’ experience in mining and resource development. A professional engineer and entrepreneur, he has held multiple senior management and director roles with public mining companies, as well as a multi-billion-dollar ETF fund. Ellis holds an MBA in international finance and a Chartered Directors designation.

Scott Dunbar, Director is a professor and head of multiple departments at the University of British Columbia, including mineral extraction and mining innovation, as well as mining engineering. He has been involved in projects around the world in regard to mining exploration, geotechnical engineering and mine design. Dunbar received his PhD in geophysics and civil engineering from Stanford University.

GoldHaven Resources Corp. (OTCQB: GHVNF), closed Monday’s trading session at $0.4379, off by 5.7063%, on 48,650 volume. The average volume for the last 3 months is 79,082 and the stock's 52-week low/high is $0.200100004/$0.870000004.

Recent News

HempFusion Wellness Inc. (TSX: CBD.U) (FWB: 8OO) (OTC: CBDHF)

The QualityStocks Daily Newsletter would like to spotlight HempFusion Wellness Inc. (TSX: CBD.U) (FWB: 8OO) (OTC: CBDHF).

  • HempFusion Wellness Inc. announces it is offering its new EU-compliant products through Boots Ireland
  • This marks the company’s official entry into the Irish market in what is a significant step in further venturing into the U.K. and Europe as a whole
  • Boots will carry HempFusion’s products in close to 50% of stores in the country
  • Following unprecedented circumstances, HempFusion announced a new Chief Financial Officer, Ms. Maria Leal, taking over from Mr. Bruce Valentine
  • Ms. Leal will oversee HempFusion’s finance and accounting functions

HempFusion Wellness (TSX: CBD.U) (OTCQX: CBDHF) (FWB: 8OO) just marked a significant milestone in its European expansion plan. This followed the announcement that it would now be offering its new European Union (“E.U.”) compliant products through its wholly-owned subsidiary, Probulin Probiotics, LLC, via Boots Ireland (https://cnw.fm/An67c).

HempFusion Wellness Inc. (TSX: CBD.U) (FWB: 8OO) (OTC: CBDHF) is a leader in the health and wellness CBD industry, providing innovative and diversified proprietary formulations utilizing the power of whole-food hemp nutrition.

Invested heavily in regulatory compliance, HempFusion aims to consistently meet and even exceed the high standards required by retailers and consumers – putting safety, quality and consistency first. In support of these efforts, the company is U.S. Hemp Authority Certified and is a current board member of the U.S. Hemp Roundtable, a coalition of leading companies committed to advancing safe hemp and CBD products.

HempFusion reported 1,750 shareholders and $18.3 million in cash as of June 30, 2020 – the second-largest cash position in its sector – with no debt. Looking ahead, the company is currently preparing to launch an IPO directly onto the Toronto Stock Exchange (“TSX”) senior board, where it has already reserved ticker symbol ‘CBD.U’. Learn More About HempFusion Upcoming IPO.

HempFusion is headquartered in Denver, Colorado.

HempFusion’s Proprietary Wellness Portfolio

The diverse product portfolio showcased by HempFusion includes 46 products that are currently on shelves. The company’s leading offerings include HempFusion-owned Biome Labs, HF Labs and Probulin. Due to the time and resources allocated to increasing the compliance of these proprietary products, HempFusion may have a competitive advantage and create additional retail opportunities that are not available for other CBD companies.

HempFusion’s Diversified Revenue Pipeline

HempFusion’s focus and investment into regulatory compliance has opened doors to major food and drug mass or big box retailers that are not available to other CBD companies. This strategic approach includes five distinct channels:

  • Natural Health Retailers
  • eCommerce
  • Big Box / Food and Drug Mass
  • Doctor Practitioner
  • Convenience

HempFusion’s Line of Products

HempFusion’s branded line of products is based on the company’s proprietary Whole Food Panoramic Full-Spectrum Hemp Complex. Each product is condition-specific, targeting needs such as sleep, energy and stress.

All of HempFusion’s products are made from DNA-verified, European Union registered, non-GMO, organic industrial hemp. The company’s offerings span multiple product categories, including:

  • Tinctures and capsules – These offerings make up the most popular product category in the $4 billion U.S. CBD market.
  • OTC topicals – HempFusion is one of the few CBD companies marketing FDA Drug Listed Topicals. The FDA compliance standards ensure that these products meet the standards set by larger national retailers.
  • Condition-specific OTC products – HempFusion has OTC products that are condition-specifically targeted, including:
    • OTC Pain Products – The global pain relief market for topicals is projected to reach $13.3 billion by 2025, with a CAGR from 2018 to 2025 of 7.4%.
    • OTC Eczema Products – The global dermatitis market is projected to reach $13.6 billion by 2026.
    • OTC Acne and Aging/Beauty Products – The global market for beauty and anti-aging products is currently estimated at $1.08 trillion.
    • OTC First Aid and Wound Healing Products – In 2019, the 10 top-selling first aid ointments in the United States generated over $650 million in sales.

Probulin Probiotics and Digestive Enzymes

Probulin Probiotics is a 100% wholly owned subsidiary of HempFusion Wellness Inc. and is currently one of the fastest growing probiotics brands in the United States, according to Spins syndicated data.

The Probulin product line addresses a wide range of consumer needs, including daily care, total care, women’s health and children’s products. The probiotics market represents a growing opportunity, as it is estimated to reach $7 billion globally by 2022.

Because of the diverse offerings of the Probulin line, it serves as HempFusion’s gateway to retailers who may not currently carry CBD products.

This ‘Trojan Horse Strategy’ is intended to allow the company to establish, develop and build relationships among these retailers. By achieving approved vendor status, the company may be able to facilitate faster onboarding times, enabling accelerated access to its CBD products in the future.

HF Labs and Biome Research – Doctor and Practitioner Product Lines

The HF Labs and Biome Research product lines are directed toward doctors and practitioners and cater to hospitals, compounding pharmacies and free-standing dispensaries. With an estimated target market of 28,000+ integrative medical doctors and 70,000+ licensed chiropractors in the United States, these offerings create a unique market opportunity as HempFusion continues to broaden its footprint in the CBD industry.

Research on CBD and Human Safety

HempFusion is one of 12 CBD companies selected to participate in ValidCare’s groundbreaking study regarding CBD and human safety, which is expected to be complete by the end of October 2020. The study is designed to address previous questions from the FDA regarding CBD products.

As part of this study, HempFusion and the other selected companies will be conducting human trials to determine if the daily use of full-spectrum hemp-derived CBD or CBD isolate impacts the human liver.

Management Team

Jason Mitchell, N.D., is the co-founder, Director and CEO of HempFusion. He has over 20 years of experience in the natural products industry and is a naturopathic doctor certified by the ANMCB. Mitchell received his doctorate from the Trinity College of Natural Health and is a member of the American Naturopathic Medical Association and the CNHP. He is an expert in supplemental formations and was responsible for successfully creating and launching over 300 industry-leading products during his 15-year tenure at Country Life Vitamins.

Ian DeQueiroz is the Chief of Brand Strategy & Partnerships and a Director for HempFusion. He is a serial entrepreneur with experience in early-stage cannabis and hemp companies. In 2010, he acquired his first cannabis CO2 extraction company in the United States. DeQueiroz has facilitated the licensing process for many companies in the United States, as well as one of Jamaica’s premier cannabis companies, Epican Medicinals Ltd.

Jon Visser is HempFusion’s Chief Revenue Officer. He has over 25 years of experience in all areas of sales and marketing, with a proven track record of consistently driving growth across all major channels. Visser was previously the Senior Vice President of Sales at Navajo Inc., a multi-national manufacturer/distributor of brands like Pennzoil Automotive Supplies, Piranha Eyewear and Navajo Inc., the largest distributor of trial- and travel-sized health and beauty products in the United States. Visser grew annual sales from $60 million to $128 million in less than three years while at Navajo Inc.

Bruce Valentine Jr. is the Chief Financial Officer of HempFusion. He has a proven track record working with high-growth companies and was named CFO of the Year in 2013 by the Northern Colorado Business Report. Valentine is the former CFO of Otter Products and has over 15 years of financial management experience.

Ola Lessard is the Chief Marketing Officer of HempFusion and is also the President of the U.S. Hemp Roundtable. She has experience in marketing creative and effective brand strategies. She is a former Vice President of Marketing at Barlean’s, an award-winning supplements provider based in Washington.

Nancy Angelini is the Director of the Doctor/Practitioner Channel. She has over 25 years as an active, licensed practitioner. Angelini travels the country as a lecturer and product manager. She is responsible for opening doors to some of the largest doctor/practitioner networks in the United States.

Daniel Brody is the Chief Corporate Officer of HempFusion. He is the co-founder and former Vice President of The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF). Brody has been instrumental in listing multiple world-class cannabis companies, including TGOD, Emblem Corp. and Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF). Before joining the cannabis industry, he spent seven years working at two leading Canadian brokerage firms.

HempFusion Wellness Inc. (CBDHF), closed Monday’s trading session at $0.3915, off by 9.7094%, on 121,779 volume. The average volume for the last 3 months is 162,869 and the stock's 52-week low/high is $0.342550009/$3.69000005.

Recent News

Grapefruit USA Inc. (OTCQB: GPFT)

The QualityStocks Daily Newsletter would like to spotlight Grapefruit USA Inc. (OTCQB: GPFT).

Grapefruit USA (OTCQB: GPFT), a premiere California-based cannabis and hemp company, has partnered with 6PAK Solutions Inc., a leading Canadian cannabis manufacturer and arm of ATG Pharma Inc. The two companies have signed an NDA and are working together to distribute Grapefruit’s patented Hourglass(TM)Time Release THC+CBD Delivery Topical Relief Cream throughout Canada. According to the announcement, Grapefruit plans to file a Notice of New Cannabis Product (“NNCP”) with Health Canada; the notice includes specific information regarding the Hourglass production process. Once GPFT receives NNCP approval, the company anticipates launching its Hourglass Time Release THC+CBD Delivery Cream across Canada. To view the full press release, visit https://ibn.fm/HJifw

Grapefruit USA Inc. (OTCQB: GPFT) is a Delaware corporation that is a fully licensed premier cannabis manufacturer and distributor in the legal cannabis marketplace with its own patented and branded line of products.

The company manufactures its patented product line and distributes it, along with other cannabis products, to all properly licensed cannabis product businesses.

Grapefruit is the only cannabis company that has harnessed cutting edge science and technology to bring patented, truly disruptive products to the medicinal and recreational cannabis marketplace, fundamentally changing the way individuals use THC, CBDs and hemp-derived CBDs and capitalizing on the rise in demand for these unique products.

Headquartered in Los Angeles, California, the company has held licensing in the state for manufacturing and distributing cannabis since 2018. Grapefruit currently owns and operates a California-licensed cannabis extraction laboratory and a licensed wholesale distribution facility in the Coachillin’ Canna-Business Park near Palm Springs, California. Grapefruit is managed by a team of experts who possess the experience, skills and resources required to succeed in the competitive cannabis marketplace.

Hourglass™ Topical Delivery Cream

Grapefruit’s patented Hourglass™ topical delivery cream has solved the previously insurmountable difficulties of efficient skin absorption of THC and other cannabinoids.

Hourglass™ allows users to experience a sustained and holistic delivery of THC/cannabinoids providing “the entourage effect” following initial application to the skin. Additional applications may be made confidently and discreetly at the user’s discretion. There simply is no other product on the planet which successfully utilizes a patented time release THC and CBD delivery mechanism to deliver the holistic benefits of cannabis to those who need it.*

Hourglass™ is a unique, highly concentrated full spectrum time-release topical delivery cream that releases a holistic amount of THC, along with a wide range of cannabinoids (or just CBD), over a four- to eight-hour period.* The formula then comes off through the natural sloughing process of dead skin cells. Hourglass provides many holistic benefits, all of which promote health and wellness as it’s number one goal.

Hourglass™ provides users with an entourage effect of THC plus a wide range of cannabinoids, including CBD, Cannabinol (CBN), Cannabigerol (CBG), Delta-8, Tetrahydrocannabivarin (THCV), and Cannabielsoin (CBE) in a Patchless Patch™ system that is novel and proprietary to the company.

Hourglass™ Topical Delivery Cream has fundamentally changed the way individuals use THC and cannabinoids to obtain their holistic benefits.* As a result, smoking cannabis or hemp flowers and orally consuming edibles, which are metabolized in the gut and liver resulting in uneven reactions, are no longer the exclusive ways to receive both the medicinal and recreational benefits of THC/cannabinoids.* Now for the first time in history, there is an effective, easy to use third choice – Hourglass™ by Grapefruit.

*This product is not regulated by the FDA and is not intended to cure, mitigate, treat or prevent disease.

Grapefruit Cannabis Services

Grapefruit distributes cannabis flower and cannabis products, including its own proprietary products, as well as a wide range of services, to other properly licensed cannabis product businesses. These products and services include:

  • Distribution – As a premier licensed distributor, Grapefruit handles the distribution of all-things cannabis throughout California, specializing in bulk AAA exotic indoor flowers sourced from farms located in the state. The wholesale distribution arm facilitates flowers, fresh and dry frozen, and oil transactions in bulk wholesale form. Its wholesale distribution arm distributes its patented Hourglass™ topical delivery cream.
  • Manufacturing – The company owns and operates a fully licensed and compliant ethanol extraction lab that produces a high-quality distillate. This THC Honey Oil distillate is a universal product used in everything, including infused edibles, tinctures, creams and even vape cartridges. Its patented Hourglass™ cream is also manufactured exclusively at Grapefruit’s Coachillin lab facility by highly trained Grapefruit personnel.
  • Hourglass™ Topical THC+CBD Delivery Cream – The company’s patented Hourglass™ Topical Delivery Cream has solved the inherent difficulties of efficient skin absorption of THC and cannabinoids such as CBD, CBN, CBG and CBC, as well as hemp-derived CBDs and cannabinoids. Hourglass™ is a truly novel and disruptive delivery technology which fundamentally changes the way individuals will use THC and CBD to obtain their holistic benefits.*
  • Rainbow Dreams – Rainbow Dreams is the company’s lifestyle brand designed for the recreational cannabis marketplace. The brand captures the party-mode of the 1970s and offers vape carts with unique cannabis strains and natural flavors. The product fulfills an important marketplace niche – a top-shelf product that is competitively priced.

Market Outlook

The global cannabis market was valued at $10.6 billion in 2018. During the forecast period from 2019 to 2026, the market is expected to grow at a CAGR of 32.92%, reaching a projected value of $97.35 billion by the end of 2026 (https://nnw.fm/eTMSX).

Cannabis legalization has been gaining momentum around the world. Grapefruit is currently in a position to disrupt the industry – both the medicinal and recreational sectors – with proprietary products and manufacturing processes that harness the power of cutting-edge science and technology.

Management Team

Bradley J. Yourist is the Chief Executive Officer of Grapefruit. Mr. Yourist has been a follower of the medical cannabis market since the late 1990s, which allows him to understand the distribution model and the legal issues facing the market. He has also seen the benefit of cannabinoids in the medical industry. He understands the planning and operations of Grapefruit’s cannabis distribution arm and extraction lab and was instrumental in the planning for the facility.

Daniel J. Yourist is the Chief Operating Officer of Grapefruit. He is a licensed attorney in the state of California and a Real Estate Broker. Mr. Yourist is a licensing expert in the cannabis space and has gained extensive experience in all areas of managing a cannabis business in California. He ensures that every aspect of the company is run in accordance with state and local cannabis laws and regulations.

Grapefruit USA Inc. (OTCQB: GPFT), closed Monday’s trading session at $0.0569, up 3.4545%, on 821,386 volume. The average volume for the last 3 months is 761,185 and the stock's 52-week low/high is $0.013624999/$0.310000002.

Recent News

Cybin Inc. (NEO: CYBN) (OTC: CLXPF)

The QualityStocks Daily Newsletter would like to spotlight Cybin Inc. (NEO: CYBN) (OTC: CLXPF).

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today released financial and business highlights for its financial year ended March 31, 2021. “It has been an incredibly busy and successful year for the Cybin team, expanding both our product development capabilities and our drug development programs,” said Doug Drysdale, CEO of Cybin. “The enormous progress that we have made serves to strengthen the foundation of our organization, upon which we plan to build further in the coming 12 months as we continue our clinical research activities. I want to thank the entire Cybin team, our board of directors and our investors for supporting the important work we are doing to revolutionize the future of mental health care.” To view the full press releases, visit https://ibn.fm/hsfB2 and https://ibn.fm/FSU8a. Also today, the company was featured in a publication from BioMedWire, examining how a study recently published in the “Journal of Clinical Psychopharmacology” has found that some domestic mass shooters in the United States suffer from psychiatric disorders that they haven’t been treated for or received medication for. The report, written by Ira D. Glick and colleagues, highlighted that while most individuals who are mentally ill aren’t violent and most who are violent aren’t mentally ill, their research would be useful to lawyers, mental health providers and the public, who needed to be aware of the fact that some unmedicated individuals pose a higher risk of violence.

Cybin Inc. (NEO: CYBN) (OTC: CLXPF) is a Canada-based life sciences company focused on the pharmaceutical development of psychedelic products, as well as the functional mushroom market.

The early-stage company boasts an experienced management team featuring industry veterans from pharmaceutical and consumer product backgrounds who have run multiple clinical trials and collectively helped facilitate billions of dollars in product revenues. The team is dedicated to the development of products and protocols within the psychedelic, pharmaceutical and nutraceutical industries.

In particular, Cybin aims to further build upon and expand its intellectual property (IP) portfolio, which is structured around unique psilocybin delivery mechanisms that target a number of different therapeutic indications. In addition, the company has dedicated itself toward furthering its research and IP within the fields of synthetic compounds, extraction methods, the isolation of chemical compounds, new drug formulations and protocol regimes.

Serenity Life Sciences & Natures Journey Inc.

The company’s business model is centered around its two core subsidiaries, Serenity Life Sciences and Natures Journey Inc., which comprise Cybin’s two-pronged approach toward delivering fungi-derived psychedelic and medicinal products.

Serenity Life Sciences is focused on furthering research and development of psilocybin-based medications. Psilocybin is found in certain species of mushrooms and is a non-habit forming, naturally occurring psychedelic compound. Research into psilocybin has shown positive results for the treatment of depression, anxiety, PTSD, addiction, eating disorders, ADHD and other indications.

Natures Journey Inc. operates the Journey brand, which specializes in developing proprietary medicinal mushroom products that target and promote mental wellness, immune boosting detoxification and overall general health and wellbeing.

Partnership with the Toronto Centre for Psychedelic Science (TCPS)

Staying true to its axiom of being a research-first medicinal mushroom life sciences company, Cybin recently announced its entry into a strategic partnership with the Toronto Centre for Psychedelic Science (TCPS), with the goal of furthering its ongoing psilocybin research efforts and expanding Cybin’s psilocybin IP portfolio (http://nnw.fm/9EUkI).

“While there is evidence to support psilocybin as a treatment for certain indications, the Toronto Centre for Psychedelic Science is taking a clinical approach to prove or disprove the safety and efficacy of psilocybin-based microdosing through an open science approach,” Paul Glavine, CEO of Cybin, stated in a news release.

“We are excited to join forces with Cybin and to offer our expertise. A number of firms had approached TCPS, but Cybin demonstrated a superior commitment to high-quality research and integrity in product development. Our high standards for scientific rigor and transparency will find a fitting home within the culture Cybin is cultivating in Canada and abroad,” Thomas Anderson, co-founder of the Toronto Centre for Psychedelic Science, added.

Journey’s Product Monetization & Market Potential for Nutraceutical Supplements

Although Cybin is at the forefront of companies seeking to conduct clinical trials aimed at gaining regulatory approval for psilocybin and other psychedelic products, the company has also placed a great deal of emphasis on generating meaningful revenue from its very outset.

Cybin’s Journey brand has is launching a range of supplements comprised of popular fungi-derived ingredients such as Reishi, Lion’s Mane and Cordyceps. Purported to aid focus and concentration while promoting neurogenesis, Journey’s range of nutraceutical products provides Cybin with a crucial foothold within the non-psychedelic legal supplement market, which is valued at over $25 billion globally and growing at a 9% year-over-year rate.

Pharmaceutical Psychedelics

In addition to the company’s range of non-psychedelic supplements, Cybin has plans to carry out a clinical trial with a new delivery system for its psilocybin-based medications later this year. Ultimately, the company aims to enter into technology transfer agreements with global pharmaceutical companies after phase 1 & phase 2 clinical trials are complete in order to accelerate regulatory approvals in major indications in global markets with entire lifecycle product management.

With products such as psilocybin truffles already legal in nations such as the Netherlands, Jamaica and Bulgaria, Cybin has positioned itself to capitalize on an eventual legalization of psychedelic mushroom-derived products in the future. Working within a regulatory environment with strong similarities to that which dealt with cannabis prior to the industry’s eventual legalization by the Canadian government in 2018, Cybin is laying the groundwork for the moment pharmaceutical psychedelics gain acceptance in North America and abroad.

Amalgamation Agreement and Financing

Cybin recently announced its entry into an amalgamation agreement dated June 26, 2020, with Clarmin Explorations Inc. (TSX.V: CX) and 2762898 Ontario Inc., a wholly owned subsidiary of Clarmin (http://nnw.fm/w04LH). Completion of the transactions contemplated in the amalgamation agreement will result in the reverse takeover of Clarmin by Cybin.

In connection with the proposed transaction, Cybin plans to complete a “best-efforts” brokered private placement of subscription receipts of Cybin, with a syndicate of agents co-led by Stifel Nicolaus Canada Inc. (Stifel GMP) and Eight Capital, to raise a minimum of C$14 million ($10 million) and a maximum of C$21 million ($15 million), with a 15% agents’ option.

To date, Cybin has raised approximately C$10,400,000 through an initial financing round and its series A financing round.

Cybin Inc. (NEO: CYBN) (OTC: CLXPF), closed Monday’s trading session at $2.35, up 6.3348%, on 1,631,686 volume. The average volume for the last 3 months is 426,725 and the stock's 52-week low/high is $0.493800014/$2.58920001.

Recent News

Lexaria Bioscience Corp. (NASDAQ: LEXX) (CSE: LXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX) (CSE: LXX).

Lexaria Bioscience Corp. (NASDAQ: LEXX) (CSE: LXX) was highlighted today by Life Sciences Investor Forum as among the companies presenting at their upcoming conference. Life Sciences Investor Forum today announced that the presentations from the June 24 th conference are now available for on-demand viewing at LifeSciencesInvestorForum.com. This virtual event showcased live company presentations and interactive discussions focused on the life sciences industry. The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download shareholder materials from the company’s “virtual trade booth”. REGISTER OR LOGIN AT: https://bit.ly/3j2S9Si

Lexaria Bioscience Corp. (NASDAQ: LEXX) (CSE: LXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 19 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Monday’s trading session at $6.88, off by 1.7143%, on 195,186 volume. The average volume for the last 3 months is 943,879 and the stock's 52-week low/high is $3.97510004/$9.46000003.

Recent News

AmpliTech Group Inc. (NASDAQ: AMPG)

The QualityStocks Daily Newsletter would like to spotlight AmpliTech Group Inc. (NASDAQ: AMPG) (NASDAQ: AMPGW).

AmpliTech Group (NASDAQ: AMPG), a designer, developer and manufacturer of state-of-the-art components and semiconductor chips for satellite and 5G communications networks, defense, space, and other commercial applications, today announced that it has joined the Russell Microcap(R) Index. The addition is in conjunction with the index's annual reconstitution, which took effect after the market’s close on June 25, 2021. “Inclusion in the Russell Microcap Index is a testament to the progress we have made positioning AmpliTech to participate in the build-out of satellite networks, 5G communications and other next-generation networks,” said AMPG CEO Fawad Maqbool. “These systems will provide enhanced data and bandwidth capabilities essential for supporting rapid growth in connected devices, entertainment and gaming content distribution, video conferencing, internet of things (‘IoT’) applications, autonomous-vehicle communications, quantum computing, space exploration and other bandwidth-intensive applications.” To view the full press release, visit https://ibn.fm/UUR6J

AmpliTech Group Inc. (NASDAQ: AMPG) (NASDAQ: AMPGW) designs, develops and manufactures custom radio frequency (RF) components for the commercial, SATCOM, space and military markets. In addition to developing new products for the 5G/6G wireless ecosystem and infrastructure, the company has placed focus on the development of leading-edge solutions in quantum computing in support of U.S. efforts to reach the coveted position of quantum supremacy. The company maintains a commitment to R&D that allows it to remain at the forefront of emerging technologies. AmpliTech aims to use its advanced techniques and IP to provide tomorrow’s technology today, improving everyone’s quality of life.

AmpliTech was founded by Fawad Maqbool in 2002 to fill the need for affordable, high-quality, customized and state-of-the-art amplifiers and components. Headquartered in Bohemia, New York, the company currently has distributors and representatives available worldwide.

Product Portfolio

AmpliTech’s mission is to develop quality, state-of-the-art microwave amplifiers by leveraging its experience, proven technical expertise and superior design heritage. The company’s products cover a frequency range from 50 kHz to 44 GHz, with plans to eventually offer designs up to 100 GHz. Its current catalog includes:

Amplifiers

Passive Components

All the company’s products come with a satisfaction guarantee, as the company is fully committed to providing only high-quality products free from manufacturing and material defects and guaranteed to perform according to applicable specifications.

Consulting Services

Leveraging more than 100 years of combined experience in microwave systems and component design ranging from active components to passive devices, AmpliTech also provides valuable consulting services and technical assistance to its customers.

With capabilities ranging from initial design to final manufacturing and delivery, the company’s team also offers project management services and advice on both technical aspects and how to handle business issues such as resource allocation, customer contact, budget restraints, time limits and more.

Other key benefits of AmpliTech consulting services that can give its customers a definitive edge include:

  • Timely technical assistance
  • Little or no learning curve
  • Less long-term costs associated with full-time employees with benefits and salaries
  • Availability when necessary
  • Customer support with schedules, project management and on the job training
  • Access to technology
  • Partnering for manufacturing and/or complete turn-key product solution
  • Personal guidance from concept to development
  • Custom designs for each application

Market Outlook

The global microwave devices market was valued at $7.44 billion in 2019 and is expected to grow at a CAGR of 3.23% and reach $9 billion by 2025 (https://nnw.fm/zqMEk). Governmental expenditures in the defense and space communications sectors are expected to expand the opportunities for growth within the industry.

AmpliTech continues to follow its strategy of identifying key elements in today’s technological revolution. It is leveraging its technical expertise and experience to align product portfolios and IP with innovation (https://nnw.fm/rVzxX). The company has plans to be a catalyst in the enhancement, development and distribution of breakthroughs in the following sizeable markets:

  • High Speed Terrestrial and Satellite Terminals (SATCOM, “Internet in the Sky”)
  • 5G/Wi-Fi6E and 6G wireless infrastructure (Cellular Base Stations, Small Cells, Private Wi-Fi Networks)
  • IoT (Internet of Things)
  • Cloud Farms, Big Data and MEC architecture
  • Quantum Supercomputers/Quantum Research
  • Deep Space Astronomy
  • Autonomous Self-Driving Vehicles
  • Telemedicine, AR/VR (Augmented and Virtual Reality)
  • Drones, UAVs (Unmanned Aerial Vehicles)
  • Cyber-security
  • Military/Defense ECM/EW

Management Team

Fawad Maqbool is the Founder, President, CEO and CTO of AmpliTech Group Inc. He has been in the microwave industry for over 30 years. Mr. Maqbool spent 14 years developing state-of-the-art amplifiers and components for MITEQ Inc., a leading microwave and communications equipment supplier. He founded AmpliComm in 2000, which was subsequently acquired by Aeroflex Inc. Mr. Maqbool has management and design experience, which has led to the development of microwave technology on a commercial and military level. He holds a B.S.E.E in Microwave Engineering and a B.S.E.E in Bio-Medical Engineering from CUNY and an M.S.E.E from the Polytechnic University of New York.

Louisa Sanfratello is the company’s CFO. She is a Certified Public Accountant (CPA) and has worked in various industries since 1998. During this time, she held roles as an accountant for charities and schools, consisting of the preparation of official financial documents and day-to-day financial management requirements. Ms. Sanfratello began her professional career in 1987 at Holtz, Rubinstein & Co., a public accounting firm. She gathered two years of experience there before gaining her CPA and taking on more challenging roles.

Brandon Worster is the company’s Director of Engineering. He joined AmpliTech at the end of 2019, bringing over 14 years of design and management experience. His specialty is Low Noise and Medium Power Amplifiers, but Mr. Worster also has vast experience with various systems, including RF/Microwave devices and systems. He holds a master’s degree in electrical engineering and is an adjunct professor at Farmingdale University in New York.

John P. Pastore is AmpliTech’s Director of Sales. He has worked in the microwave industry for more than 35 years, including time with some of the industry’s leading names. Mr. Pastore is a hands-on professional who has experience that spans over 20 years with progressive roles that blend technical, manufacturing, customer service and management expertise. He is an extremely valuable asset to the company as it moves forward due to his business savvy approach and deep industry knowledge. He has a B.S. in Business Management.

M. Syed handles Technical Sales and is the company’s Director of IT. He is an electrical engineer with more than 10 years of business experience. Since 2011, he has led Technical Sales for AmpliTech, and he recently became the President and CEO of his own company while also serving as Chief Technical Sales consultant for numerous other companies and groups in New York City. Mr. Syed has been in the IT industry for 25 years. He is a Computer Engineer by trade and a Certified Netware Engineer and Microsoft Certified Systems Engineer.

AmpliTech Group Inc. (AMPG), closed Monday’s trading session at $4.88, off by 0.610998%, on 170,624 volume. The average volume for the last 3 months is 694,931 and the stock's 52-week low/high is $0.879999995/$19.7999992.

Recent News

>

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.